US 20220144920A1

(19) United States

(12) Patent Application Publication

(10) Pub. No.: US 2022/0144920 A1

(43) Pub. Date: May 12, 2022

STEVENS et al.

(54) ENGINEERING MONOCLONAL ANTIBODIES TO IMPROVE STABILITY AND PRODUCTION TITER

(71) Applicant: **AMGEN INC.**, Thousand Oaks, CA (US)

(72) Inventors: **Jennitte LeAnn STEVENS**, Thousand Oaks, CA (US); **Deniz TEMEL**, Acton, MA (US); **Bram ESTES**, Camarillo, CA (US); **Neeraj Jagdish AGRAWAL**, Natick, MA (US)

(21) Appl. No.: **17/420,231**

(22) PCT Filed: **Jan. 2, 2020**

(86) PCT No.: **PCT/US2020/012057**

§ 371 (c)(1),
(2) Date: **Jul. 1, 2021**

Related U.S. Application Data

(60) Provisional application No. 62/787,867, filed on Jan. 3, 2019.

Publication Classification

(51) **Int. Cl.**
C07K 16/00 (2006.01)

(52) **U.S. Cl.**
CPC ***C07K 16/00*** (2013.01); *C07K 2317/94* (2013.01); *C07K 2317/31* (2013.01); *C07K 2317/24* (2013.01); *C07K 2317/21* (2013.01)

(57) **ABSTRACT**

Presented herein are methods directed to engineering monoclonal antibodies and antibody variants to improve stability and their production in culture. Specifically, the monoclonal antibodies can be engineered at heavy chain residue 56 (AHo numbering) to a glycine, alanine, or serine, and/or engineered at position 80 (AHo) to be a hydrophobic residue such as alanine, isoleucine, phenylalanine, leucine, methionine, or valine.